<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS134154</article-id>
<article-id pub-id-type="doi">10.1101/2021.08.23.457314</article-id>
<article-id pub-id-type="archive">PPR387428</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Switching of OAS1 splicing isoforms mitigates SARS-CoV-2 infection</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Iida</surname>
<given-names>Kei</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="fn" rid="FN1">*</xref>
<xref ref-type="fn" rid="FN2">#</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ajiro</surname>
<given-names>Masahiko</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="fn" rid="FN1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Muramoto</surname>
<given-names>Yukiko</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Takenaga</surname>
<given-names>Toru</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Denawa</surname>
<given-names>Masatsugu</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kurosawa</surname>
<given-names>Ryo</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Noda</surname>
<given-names>Takeshi</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Hagiwara</surname>
<given-names>Masatoshi</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
<xref ref-type="fn" rid="FN2">#</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Medical Research Support Center, Graduate School of Medicine, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan</aff>
<aff id="A2">
<label>2</label>Department of Drug Discovery Medicine, Graduate School of Medicine, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan</aff>
<aff id="A3">
<label>3</label>Department of Anatomy and Developmental Biology, Graduate School of Medicine, Kyoto University, Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan</aff>
<aff id="A4">
<label>4</label>Laboratory of Ultrastructural Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan</aff>
<aff id="A5">
<label>5</label>CREST, Japan Science and Technology Agency, 4-1-8 Honcho, Kawaguchi, Saitama 332-0012, Japan</aff>
<author-notes>
<corresp id="CR1">
<underline>Corresponding authors:</underline> Kei Iida, PhD, Research Assistant Professor, Medical Research Support Center, Graduate School of Medicine, Kyoto University Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan, <email>iida.kei.3r@kyoto-u.ac.jp</email>, Masatoshi Hagiwara, MD, PhD, Professor, Department of Anatomy and Developmental Biology Graduate School of Medicine, Kyoto University Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, Japan, <email>hagiwara.masatoshi.8c@kyoto-u.ac.jp</email>
</corresp>
<fn id="FN1">
<label>*</label>
<p id="P1">These authors share first authorship.</p>
</fn>
<fn id="FN2">
<label>#</label>
<p id="P2">These authors share last authorship.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>08</day>
<month>09</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="preprint">
<day>23</day>
<month>08</month>
<year>2021</year>
</pub-date>
<permissions>
<ali:free_to_read/>
<license>
<ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0 International license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<sec id="S1">
<title>Background</title>
<p id="P3">The rapidly accumulating disease susceptibility information collected from coronavirus disease (COVID-19) patient genomes must be urgently utilized to develop therapeutic interventions for SARS-CoV-2 infection. Chromosome 12q24.13, which encodes the 2'-5'-oligoadenylate synthetase (OAS) family of proteins that sense viral genomic RNAs and trigger an antiviral response, is identified as one of the genomic regions that contains SNPs associated with COVID-19 severity. A high-risk SNP identified at the splice acceptor site of <italic>OAS1</italic> exon 6 is known to change the proportions of the various splicing isoforms and the activity of the enzyme.</p>
</sec>
<sec id="S2">
<title>Methods</title>
<p id="P4">We employed <italic>in-silico</italic> motif search and RNA pull-down assay to define a factor responsible for the <italic>OAS1</italic> splicing. Next, we rationally selected a candidate for slicing modulator to modulate this splicing.</p>
</sec>
<sec id="S3">
<title>Results</title>
<p id="P5">We found that inhibition of CDC-like kinase with a small chemical compound induces switching of <italic>OAS1</italic> splice isoforms in human lung cells. In this condition, increased resistance to SARS-CoV-2 infection, enhanced RNA degradation, and transcriptional activation of interferon β1, were also observed.</p>
</sec>
<sec id="S4">
<title>Conclusions</title>
<p id="P6">The results indicate the possibility of using chemical splicing modifiers aided by genome-based precision medicine to boost the innate immune response against SARS-CoV-2 infection.</p>
</sec>
</abstract>
<kwd-group>
<kwd>SARS-CoV-2</kwd>
<kwd>OAS-1</kwd>
<kwd>splice forms</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="S5" sec-type="intro">
<title>Introduction</title>
<p id="P7">As of July 2021, more than 180 million people have been infected with SARS-CoV-2 and more than 4.0 million people have died of COVID-19 (<ext-link ext-link-type="uri" xlink:href="https://covid19.who.int">https://covid19.who.int</ext-link>). Despite extensive efforts towards prophylactic vaccination against SARS-CoV-2, the incidence of COVID-19 continues to increase, with rapid emergence of mutant strains (<ext-link ext-link-type="uri" xlink:href="https://www.who.int/">https://www.who.int/</ext-link>). To understand SARS-CoV-2 pathogenesis and develop novel therapeutic approaches, it is essential to analyze genetic factors responsible for susceptibility and severity. A previous genome-wide association study (GWAS) in over 2,000 COVID-19 patients uncovered several susceptibility-associated genes, including <italic>LZTFL1</italic>, <italic>CCHCR1</italic>, <italic>OAS1</italic>, <italic>OAS2</italic>, <italic>OAS3</italic>, <italic>DPP9</italic>, <italic>TYK2</italic>, and <italic>IFNAR2</italic> (<xref ref-type="bibr" rid="R20">Pairo-Castineira et al., 2021</xref>). The COVID-19 host genetics initiative also gathered genetic information for more than 30,000 COVID-19 patients, including over 5,000 patients with very severe respiratory symptoms, and showed the similar results (<xref ref-type="bibr" rid="R28">The COVID-19 Host Genetics Initiative, 2021</xref>). It revealed 131 SNPs associated with severe respiratory conditions (p &lt; 5 × 10<sup>−8</sup>) in the gene cluster of <italic>OAS1</italic>, <italic>OAS2</italic>, and <italic>OAS3</italic> (<xref ref-type="fig" rid="F1">Fig. 1a</xref>). They consist of 5 SNPs within the <italic>OAS1</italic> locus, 72 SNPs within intergenic regions across <italic>OAS1</italic>, <italic>OAS2</italic>, and <italic>OAS3</italic>, 46 SNPs within the <italic>OAS3</italic> locus, and 8 SNPs within the <italic>OAS2</italic> locus. Importance of the <italic>OAS</italic> family of genes was further indicated in a transcriptome study in an <italic>in vitro</italic> model of SARS-CoV-2 infection (<xref ref-type="bibr" rid="R2">Blanco-Melo et al., 2020</xref>), in which normal human bronchial epithelial (NHBE) cells exhibited an increased expression of <italic>OAS1</italic>, <italic>OAS2</italic>, and <italic>OAS3</italic> (2.3, 2.1, and 2.2-fold increase, respectively). Of the aforementioned SNPs, this genomic region includes SNPs associated with hospitalized COVID-19 patients (32 SNPs) and all COVID-19 patients (125 SNPs) with low p-values (p &lt; 5 × 10<sup>−8</sup>) (<xref ref-type="fig" rid="F1">Fig. 1b, 1c</xref>), which are concentrated around the terminal exon of <italic>OAS1</italic> and intron 2 of <italic>OAS3</italic>. Amongst them, the SNP with the lowest p-value was the G&gt;A SNP rs10774671, located at the last base of intron 5 (<xref ref-type="table" rid="T1">Table 1</xref>), and its association with infectious viruses, including SARS coronavirus and Dengue virus, has been reported (<xref ref-type="bibr" rid="R8">Hamano et al., 2005</xref>; <xref ref-type="bibr" rid="R10">He et al., 2006</xref>; <xref ref-type="bibr" rid="R14">Lin et al., 2009</xref>).</p>
</sec>
<sec id="S6" sec-type="materials | methods">
<title>Materials and Methods</title>
<sec id="S7">
<title>Analysis of GWAS data</title>
<p id="P8">GWAS results were obtained from the COVID-19 Host Genetics Initiative data. The following terms were used: “A2_ALL_leave_23andme” for GWAS of confirmed COVID patients with very severe respiratory conditions vs. population, “B2_ALL_leave_23andme” for GWAS of hospitalized COVID patients vs. population, and “C2_ALL_leave_23andme” for GWAS of all COVID patients vs. population. Data version round 5 was used for all the data obtained in this study (January 18, 2021). The sample size of 5582, 12888, and 36590 individuals were chosen for evaluation of GWAS datasets of severe respiratory symptoms, hospitalization, and COVID-19 susceptibility, respectively, obtained from COVID-19 host genome initiative database (<xref ref-type="bibr" rid="R28">The COVID-19 Host Genetics Initiative, 2021</xref>). This sample number was determined based on number of applicable data without exclusion, and a sample-size estimation was not conducted prior to the analysis.</p>
</sec>
<sec id="S8">
<title>Cell lines</title>
<p id="P9">Daudi cells, derived from Burkitt’s lymphoma, were obtained from the cell bank of the National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN, Osaka, Japan) and maintained in RPMI 1640 medium (Nacalai Tesque, Kyoto, Japan) supplemented with 20% fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin. Calu-3 cells, derived from lung adenocarcinoma, were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA), and cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Nacalai Tesque) supplemented with 10 % fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin. All cells were maintained in an incubator at 37 °C with 5 % CO<sub>2</sub>, and mycoplasma was confirmed negative in routine polymerase chain reaction tests. VeroE6/TMPRSS2 cells were obtained from JCRB Cell Bank, and cultured in Dulbecco’s modified Eagle’s medium (DMEM) (Sigma-Aldrich) supplemented with 10 % fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin. The cells were maintained in an incubator at 37 °C with 5 % CO2.</p>
</sec>
<sec id="S9">
<title>RNA pull-down assay and western blot</title>
<p id="P10">Calu-3 whole cell lysates were prepared using a lysis buffer containing 10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid, 1% Triton X-100, 0.1% sodium dodecyl sulphate, 0.25% sodium deoxycholate, and 10% glycerol with protease inhibitors (Nacalai Tesque) and phosphatase inhibitors (Sigma-Aldrich, Munich, Germany), followed by sonication, treatment with DNase I (Promega, Madison, WI, USA) at 37 °C for 5 min, and centrifugation (24,000 <italic>x g</italic> at 4 °C for 15 min). The supernatant was used as the soluble fraction for the RNA-pull down assay.</p>
<p id="P11">For the RNA pull-down assay, 5'-biotin, 3'-dTdT-attached RNA, designed for the sequence adjacent to the <italic>OAS1</italic> exon 5 splice donor (5'-CUGCUGGUGAGACCUCCUGCUUCC-3' (oAM685), was incubated with NeutrAvidin beads (Thermo Fisher Scientific, Waltham, MA, USA) for 2 h at 4 °C (no bait RNA was used for the negative control), followed by wash with 1X TBS thrice. RNA-bound NeutrAvidin beads were then incubated with the Calu-3 cell lysate in the presence of 1% DMSO or 10 μM CaNDY for 16 h with rotation at 4 °C. This was followed by washing thrice with tris-buffered saline and elution with Laemmli buffer. Three technical replicates for RNA pull-down assay were independently conducted, three times from a stocked cell lysate. Eluted proteins were then analyzed by western blotting with anti-U1-70k mouse monoclonal antibody (9C4.1) (05-1588, Merk Millipore, Burlington, MA, USA) at a dilution of 1:500 for the detection of U1-70k, anti-SR protein (1H4G7) mouse monoclonal antibody (33-9400, Thermo Fisher Scientific, Waltham, MA, USA) at a dilution of 1:200 for phosphorylated SRSF6, and anti-β-actin (ACTB) mouse monoclonal antibody (Ac-15) (sc-69879, Santa Cruz Biotechnology, Dallas, TX, USA) at a dilution of 1:4,000 for ACTB. Chemiluminescent signals were detected using a ChemiDoc MP Imaging System (Bio-Rad, Hercules, CA, USA).</p>
</sec>
<sec id="S10">
<title>Transcriptome analysis for CaNDY-treated Calu-3 cells</title>
<p id="P12">RNAs were extracted using RNeasy Mini kit (QIAGEN, Hilden, Germany) from Calu-3 cells, treated with 10 μM CaNDY or 0.1% DMSO for 18 h, and applied for RNA-Seq analysis. Three technical replicates for RNA-Seq, where each experiment was independently conducted three times from a stocked total RNA. RNA-seq reads were mapped to the human genome sequences (GRCh38) using STAR (ver. 2.7.1a, <ext-link ext-link-type="uri" xlink:href="https://github.com/alexdobin/STAR">https://github.com/alexdobin/STAR</ext-link>) with ENCODE options, using the Ensembl genome annotation (ver. 102). Raw reads were counted with bam files, and TPM values were calculated using RSEM v1.2.31 (<ext-link ext-link-type="uri" xlink:href="https://github.com/deweylab/RSEM">https://github.com/deweylab/RSEM</ext-link>). Differentially expressed genes were identified using the method described above. Differential alternative splicing (DAS) events were analyzed with the method previously described (<xref ref-type="bibr" rid="R22">Sakuma et al., 2015</xref>) using the rMATS program (<ext-link ext-link-type="uri" xlink:href="http://rnaseq-mats.sourceforge.net/rmats4.1.1/">http://rnaseq-mats.sourceforge.net/rmats4.1.1/</ext-link>). DAS was defined by the following criteria: FDR &lt; 0.01, read counts ≥ 15, and delta Percent Spliced-In (PSI) ≥ 0.05. We compared the DAS events with the gene annotation information, then classified the event types into events on the exons constituting the productive mRNAs, events on additional exons/regions of the productive mRNAs, and others. For characterizing gene set and transcriptome profiles, we used the Metascape website (<ext-link ext-link-type="uri" xlink:href="https://metascape.org/">https://metascape.org/</ext-link>) and Gene Set Enrichment Analysis (GSEA, <ext-link ext-link-type="uri" xlink:href="https://www.gsea-msigdb.org/gsea/">https://www.gsea-msigdb.org/gsea/</ext-link>). The same samples were also used for RT-PCR.</p>
</sec>
<sec id="S11">
<title>SARS-CoV-2 infection</title>
<p id="P13">Calu-3 cells were pre-treated with 10 μM CaNDY or 0.1% DMSO for 24 h, infected with SARS-CoV-2 (SARS-CoV-2/Hu/DP/Kng/19-027) at a multiplicity of infection of 0.01, and maintained in the presence of 10 μM CaNDY or 0.1% DMSO. RNA samples were collected from the cells 24 h post-infection (pi), and the virus titers were determined by the 50% tissue culture infectious dose (TCID<sub>50</sub>) using VeroE6/TMPRSS2 cells at 48 h pi. Titer assay was conducted in six biological replicates for independent cell cultures.</p>
</sec>
<sec id="S12">
<title>Analysis of RNA degradation</title>
<p id="P14">RNA samples were diluted to 200 ng/μL. The quality of the diluted RNA samples was evaluated using the Agilent RNA 6000 Nano Kit and the Agilent 2100 Bioanalyzer. For the infected cells, three biological replicates with independent cell cultures were prepared for DMSO and CaNDY treatments, respectively, with the method described above. Total RNA from transcriptome analysis represented uninfected control for this study. The gel-like image of the 2100 Bioanalyzer result was visualized using the 2100 Expert Software (ver. B.02.11, Agilent Technologies) in pseudo colors with default settings. For detailed analyses, the migration time and fluorescence unit data were extracted in CSV format as aligned with the sample data. Next, the fluorescence unit values were normalized to an RNA concentration of 300 ng/μL. We selected the data located between 43.3 s and 48.0 s of the migration time as cleaved RNA products and those between 49.9 s and 51.4 s as the 28S rRNA. The sums of the fluorescence unit values were used for further analysis. For drawing the bar plot, the values were scaled to the mean values of DMSO samples.</p>
</sec>
<sec id="S13">
<title>RT-PCR</title>
<p id="P15">Total RNA extracted from cultured cells was used for reverse transcription using the PrimeScript RTase (Takara Bio, Shiga, Japan) with random hexamers, and the products were then amplified with ExTaq DNA polymerase (Takara Bio) with target-specific primer sets. Primers used in RT-PCR are listed in <xref ref-type="supplementary-material" rid="SD1">Table S1</xref>. Detection of RT-PCR products was conducted using the ChemiDoc MP Imaging System (Bio-Rad), with subsequent analysis by Image Lab software (Bio-Rad). RT-PCR was conducted in three technical replicates for a total RNA sample.</p>
</sec>
<sec id="S14">
<title>Modelling of the viral infection</title>
<p id="P16">The statistical simulation of SARS-CoV-2 infections was performed with the SIR (Susceptible, Infectious, or Recovered) model (<xref ref-type="bibr" rid="R9">Harko et al., 2014</xref>) using the “deSolve” package (<xref ref-type="bibr" rid="R27">Soetaert et al., 2010</xref>) in the R environment. We assigned the initial number of susceptible persons as 9999 and infectious person as 1. Beta, a parameter for infection rate per day, per person, was set as 0.5 or 0.28 (i.e., 0.5 × 0.56), and Gamma, a parameter for the removal or the recovery rate per day, per person, was set as 0.1, according to a report on the spread of SARS-CoV-2 in April 2020, in the USA (<xref ref-type="bibr" rid="R1">Adam, 2020</xref>).</p>
</sec>
</sec>
<sec id="S15" sec-type="results">
<title>Results</title>
<sec id="S16">
<title>OAS1 splice variant regulation by SRSF6</title>
<p id="P17">The rs10774671 A/G SNP is known to control the production of <italic>OAS1</italic> splice variants. The G allele of rs10774671 (G-allele) creates the AG-dinucleotide that is essential for the recognition of the exon 6 splice acceptor site for <italic>p46</italic> variant production. The A allele of rs10774671 (A-allele) leads to the alternative splicing of <italic>OAS1</italic> pre-mRNA to produce <italic>p42, p48, p44a</italic>, and <italic>p44b</italic> variants (<xref ref-type="bibr" rid="R19">Noguchi et al., 2013</xref>) (<xref ref-type="fig" rid="F2">Fig. 2a</xref>). OAS1 protein senses the double-stranded RNA structure, including RNA duplication intermediates of SARS-CoV-2 (<xref ref-type="bibr" rid="R21">Sadler and Williams, 2008</xref>; <xref ref-type="bibr" rid="R23">Schlee and Hartmann, 2016</xref>), to synthesize 2'-5'-oligoadenylates, which in turn trigger the activation of latent ribonuclease L (RNase L) for viral RNA degradation (<xref ref-type="bibr" rid="R21">Sadler and Williams, 2008</xref>; <xref ref-type="bibr" rid="R23">Schlee and Hartmann, 2016</xref>). Previous studies revealed that the catalytic activity of OAS1 varies with its splice variants; p46, the major isoform of OAS1 produced in the presence of the G-allele, presents optimal activity, while p42, the major isoform produced in the presence of the A-allele, shows poor activity (<xref ref-type="bibr" rid="R3">Carey et al., 2019</xref>; <xref ref-type="bibr" rid="R6">Di et al., 2020</xref>).</p>
<p id="P18">In A-allele individuals, disruption of the exon 6 splice acceptor site induces <italic>OAS1</italic> alternative splicing, yielding <italic>p44a</italic>, <italic>p44b</italic>, and <italic>p48</italic> through activation of acceptor sites downstream of the exon 5, and <italic>p42</italic> as a consequence of the skipped recognition of exon 5 donor site (<xref ref-type="fig" rid="F2">Fig. 2a</xref>). Assuming that the splice-shift from the inactive <italic>p42</italic> to other variants may improve the immune-response that is weakened due to the presence of <italic>OAS1</italic> A-allele, we first looked into the mechanism by which <italic>p42</italic> variant is dominantly produced. In searching for splice motifs surrounding the <italic>OAS1</italic> exon 5 donor sites with the ESEfinder tool (<xref ref-type="bibr" rid="R4">Cartegni et al., 2003</xref>), we noticed a binding motif for serine/arginine-rich splicing factor 6 (SRSF6) (5'-UGCUUC-3') immediately downstream to the exon 5 donor site (<xref ref-type="fig" rid="F2">Fig. 2b</xref>). We then speculated that SRSF6 interaction with this site could prevent U1snRNP from binding to the exon 5 donor site. To test this hypothesis, we applied a pan-CDC-like kinase (CLK) inhibitor, CaNDY, to dissociate SRSF6 from RNA by preventing the kinase activity of CLK to phosphorylate RS domain at the carboxyl-terminal of SRSF6 (<xref ref-type="bibr" rid="R26">Shibata et al., 2020</xref>). Following an RNA pull-down assay, we found that the U1snRNP binding to exon 5 donor site was enhanced when Calu-3 cells were treated with CaNDY, as represented by the detection of the U1-70k major subunit in the pull-down products, whereas phosphorylated SRSF6 not detected (<italic>OAS1SD</italic> pull-down products in <xref ref-type="fig" rid="F2">Fig. 2c</xref>). Together, these data indicate that SRSF6 plays a major role in the exon 5 donor site recognition, which is crucial for <italic>OAS1</italic> alternative splicing.</p>
</sec>
<sec id="S17">
<title>CaNDY induces splice shift in A-allele</title>
<p id="P19">Next, we investigated the consequence of CLK inhibition on alternative splicing of <italic>OAS1</italic> mRNA with A-allele. Calu-3 cells, lung adenocarcinoma cells homozygous for <italic>OAS1</italic> A-allele (<xref ref-type="supplementary-material" rid="SD1">Fig. S1a</xref>), were treated with 10 μM CaNDY or DMSO and analyzed for <italic>OAS1</italic> splicing profiles, along with Daudi cells, which are lymphoma cells homozygous for the G-allele (<xref ref-type="supplementary-material" rid="SD1">Fig. S1b</xref>). Consistent with previous observations (<xref ref-type="bibr" rid="R13">Kjær et al., 2014</xref>; <xref ref-type="bibr" rid="R19">Noguchi et al., 2013</xref>), we found that the <italic>p46</italic> variant was dominantly expressed from <italic>OAS1</italic> G-allele, while the <italic>p42</italic> variant was expressed from the A-allele (<xref ref-type="fig" rid="F2">Fig. 2d</xref>). Intriguingly, CLK inhibition induced splice-switching for <italic>OAS1</italic> with the A-allele, by suppressing <italic>p42</italic> splicing while promoting <italic>p44a</italic> and <italic>p44b</italic> variant production. This observation is consistent with the model suggested by the RNA pull-down assay (<xref ref-type="fig" rid="F2">Fig. 2c</xref>), where the exon 5 donor site is made available for U1snRNP binding upon CLK inhibition (<xref ref-type="fig" rid="F2">Fig. 2b</xref>). However, the <italic>p48</italic> variant expression was under the detection limit in both A- and G-alleles (<xref ref-type="fig" rid="F2">Fig. 2d</xref>). The splicing shift of <italic>OAS1</italic> with A-allele upon CLK inhibition was also evident in RNA-Seq analysis of Calu-3 cells, in which the <italic>p42</italic> variant was suppressed by 51%, and <italic>p44a</italic> and <italic>p44b</italic> were increased by 130% and 100%, respectively; the <italic>p44b</italic> variant was found to be a minor form of <italic>OAS1</italic>, accounting for 1-4% of <italic>OAS1</italic> transcripts (<xref ref-type="fig" rid="F2">Fig. 2e, 2f</xref>). Additionally, through the RNA-Seq analysis of Calu-3 cells with or without CaNDY treatment, we identified differential expression of 98 genes, and splice alterations yielding protein-coding variants for 63 genes; however, none of these events were associated with viral infection except for the <italic>OAS1</italic> splice alterations (<xref ref-type="supplementary-material" rid="SD1">Tables S2, S3, and Fig. S2</xref>).</p>
</sec>
<sec id="S18">
<title>SARS-CoV-2 resistance with splice shift</title>
<p id="P20">We examined the alternation of SARS-CoV-2 infection rate in Calu-3 cells, when the splicing isoform was changed from <italic>p42</italic> to <italic>p44a</italic> by manipulating the splicing phenomenon with a small chemical compound. To sufficiently change the balance of the splicing isoforms, cells were pre-treated with CaNDY for 24 h. Viral titer was assayed 2 days after cells were exposed to the virus (<xref ref-type="fig" rid="F3">Fig. 3a</xref>). The virus titer decreased from 5.18 × 10<sup>7</sup> to 2.90 × 10<sup>7</sup> (fold change = 0.56) in the cells treated with CaNDY (<xref ref-type="fig" rid="F3">Fig. 3b</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S4</xref>). There are no reports on the enzyme activity or antiviral activity of the p44a variant; however, based on our results, it can be assumed that the product encoded by <italic>p44a</italic> has stronger enzyme activity/antiviral ability than that encoded by the <italic>p42</italic> form. Furthermore, RNA degradation products were measured to confirm whether this change was indeed due to the switching of <italic>OAS1</italic> splicing isoforms. If enzyme activities of the product encoded by <italic>OAS1</italic> are elevated, elevated activities of RNase L are expected to be observed. Activated RNase L can not only degrade the foreign RNA molecules, but also the endogenous ribosomal RNA within the host cells (<xref ref-type="bibr" rid="R14">Lin et al., 2009</xref>). Thus, degradation of rRNA was investigated as a measure of RNase L activity. We confirmed the appearance of a band that is expected to be a degradation product of rRNA in cells infected with SARS-CoV-2 (<xref ref-type="fig" rid="F3">Fig. 3c</xref>). We also confirmed that the concentration of decomposition products, sized 2,000–3,000 nucleotides, increased slightly (fold change = 1.35), with a decrease in the molecular weight and concentration of the 28S rRNA peak (fold change = 0.56), upon CaNDY treatment (<xref ref-type="fig" rid="F3">Fig. 3c</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig. S3</xref>). It is known that degraded dsRNA activates the transcription of the interferon genes through the OASL and RIG-I related pathways (<xref ref-type="bibr" rid="R5">Choi et al., 2015</xref>; <xref ref-type="bibr" rid="R12">Ibsen et al., 2015</xref>). We confirmed that CaNDY treatment increases the transcription of <italic>interferon β1</italic> (<italic>IFNB1</italic>) during viral infection (<xref ref-type="fig" rid="F3">Fig. 3d, 3e</xref>). This result was consistent with the previous reports showing <italic>IFNB1</italic> transactivation during viral infections (<xref ref-type="bibr" rid="R7">Ford and Thanos, 2010</xref>; <xref ref-type="bibr" rid="R24">Schwanke et al., 2020</xref>).</p>
<p id="P21">These results indicate that CaNDY treatment enhances the infection-dependent RNase L pathway, and the type I interferon pathway induced by the degraded RNAs, via a switching of <italic>OAS1</italic> splicing isoforms from <italic>p42</italic> to <italic>p44a</italic> in Calu-3 cells (<xref ref-type="fig" rid="F3">Fig. 3f</xref>).</p>
</sec>
</sec>
<sec id="S19" sec-type="discussion">
<title>Discussion</title>
<p id="P22">In this study, we show that the difference in the balance of <italic>OAS1</italic> splicing isoforms affects the infectivity of SARS-CoV-2 in cells via modulation of the innate immune response. This result strongly suggests that the <italic>OAS1</italic> intervening sequence (IVS) 5-1 G&gt; A SNP that alters the <italic>OAS1</italic> splicing pattern is one of the important therapeutic targets for COVID-19. We recently reported on CaNDY as a potential therapeutic drug for cystic fibrosis caused by a point mutation in the <italic>CFTR</italic> gene (<xref ref-type="bibr" rid="R26">Shibata et al., 2020</xref>). In this study, we found that CaNDY treatment increased the yield of the <italic>p44a</italic> splice form (<xref ref-type="fig" rid="F2">Fig. 2d, 2e, 2f</xref>) and made the Calu-3 cells more resistant to viral infection (<xref ref-type="fig" rid="F3">Fig. 3b</xref>), suggesting that CaNDY treatment could overcome A-allele-derived vulnerabilities to SARS-CoV-2 infections.</p>
<p id="P23">The G-allele of SNP rs10774671 produces the <italic>p46</italic> splice variant, which possesses 56 amino acids at the C-terminus, compared to the 18 completely different amino acids present in the <italic>p42</italic> splice variant produced by the A-allele. This changes the localization of the OAS1 protein and its interacting partners (<xref ref-type="bibr" rid="R13">Kjær et al., 2014</xref>), which may be linked to the differential 2’-5’-oligoadenylate synthesis activities, RNase L activation, and interferon pathway activation. Several clinical trials that investigate the efficacy of an intervention of the interferon β pathway to affect the progression of COVID-19 have been conducted successfully (<xref ref-type="bibr" rid="R11">Hung et al., 2020</xref>; <xref ref-type="bibr" rid="R17">Monk et al., 2021</xref>; <xref ref-type="bibr" rid="R25">Shalhoub, 2020</xref>). On the other hand, inhibition of the interferon pathway is considered important to prevent cytokine storms in patients with severe COVID-19 (<xref ref-type="bibr" rid="R18">Nile et al., 2020</xref>). Since the <italic>OAS1</italic> IVS5-1 SNP can alter the response intensity of the interferon β pathway, stratification of COVID-19 patients depending on this SNP may assist in choosing the best course of interferon treatment.</p>
<p id="P24">It is reported that protective SNPs at <italic>OAS1/OAS3</italic>/<italic>OAS2</italic> loci originated in the Neanderthals (<xref ref-type="bibr" rid="R29">Zeberg and Pääbo, 2021</xref>; <xref ref-type="bibr" rid="R30">Zhou et al., 2021</xref>). Interestingly, the <italic>OAS1</italic> IVS5-1 A-allele, which was confirmed to be associated with the aggravation of COVID-19 in this study, was not found in the ancient human genome, the sequenced Neanderthal genome, or the Denisovan genome (<xref ref-type="bibr" rid="R16">Mendez et al., 2013</xref>). This suggests that the G to A mutation at the <italic>OAS1</italic> IVS5-1 position occurred at a relatively modern age in human history. The <italic>OAS1</italic> IVS5-1 A-allele has expanded to become a major allele in the population, especially in the Asian region (<xref ref-type="supplementary-material" rid="SD1">Fig. S4</xref>) (<xref ref-type="bibr" rid="R15">Marcus and Novembre, 2017</xref>). This suggests the possibility that this variant has some positive effects on human survival, trading off the effect of weakening resistance against viruses.</p>
<p id="P25">The results obtained in this study indicate that the <italic>OAS1</italic> IVS5-1 SNP is involved in the exacerbation of COVID-19 by eliciting changes in the <italic>OAS1</italic> splicing isoform balance. Individuals with the A-allele may have a higher risk for SARS-CoV-2 infection and its aggravation than those with the G-allele. However, we successfully demonstrate a way to overcome these genetic risks by modulating the splicing phenomenon. Splicing modulation decreased the virus infection rate 0.56 times in cell-based assays (<xref ref-type="fig" rid="F3">Fig. 3b</xref>). This theoretically implies that the peak number of SARS-CoV-2-infected individuals will be reduced by 42%, if we can alter the <italic>OAS1</italic> splicing patterns for all the individuals carrying the <italic>OAS1</italic> IVS5-1 A-allele and boost the immunity of the entire population (simulation using the <underline>S</underline>usceptible, <underline>I</underline>nfected and <underline>R</underline>emoved (SIR) model, see Methods for details). We hope that this approach based on genome-based precision medicine with a splicing modulator will contribute to the management of the COVID-19 pandemic.</p>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplementary Material</label>
<media xlink:href="EMS134154-supplement-Supplementary_Material.pdf" mimetype="application" mime-subtype="pdf" id="N66616" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S20">
<title>Acknowledgments</title>
<p>We would like to thank Editage [<ext-link ext-link-type="uri" xlink:href="http://www.editage.com">http://www.editage.com</ext-link>] for editing and reviewing this manuscript for English language.</p>
<sec id="S21">
<title>Funding</title>
<p>This study was supported by grants 15H05721 (to M.H., K.I., and M.A.), 19K07367 (to M.A.) and 20K07310 (to K.I.) from the Japan Society for the Promotion of Science, the Kansai Economic Federation (KANKEIREN) (to M.H.), Research Program on Emerging and Re-emerging Infectious Disease grants JP20fk0108270 (to M.H. and T.N.) and JP20ek0109327 (to M.H., and M.A.) from AMED, the JST Core Research for Evolutional Science and Technology grant JPMJCR20HA (to T.N.), and the Grant for Joint Research Project of the Institute of Medical Science, University of Tokyo, and the Joint Usage/Research Center program of Institute for Frontier Life and Medical Sciences Kyoto University (to T.N.).</p>
</sec>
</ack>
<sec id="S22" sec-type="data-availability">
<title>Data Availability</title>
<p id="P26">The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. The original RNA-seq data were deposited at the Gene Expression Omnibus (GEO) of National Center for Biotechnology Information (NCBI) with the accession ID GSE174398.</p>
</sec>
<fn-group>
<fn id="FN3" fn-type="conflict">
<p id="P27">
<bold>Conflict of Interest</bold>
</p>
<p id="P28">M.H. is a founder, shareholder, and member of the scientific advisory board of KinoPharma, Inc., and BTB Drug Development Research Center Co., Ltd. All other authors have no competing interests.</p>
</fn>
<fn id="FN4" fn-type="con">
<p id="P29">
<bold>Author Contributions</bold>
</p>
<p id="P30">K.I. conducted bioinformatics analysis. M.A., M.D., and R.K. conducted biological experiments relating cultured cells. Y.M., T.T., and T.N. conducted viral experiments. K.I., M.A., and M.H. wrote the paper.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adam</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>A guide to R — the pandemic’s misunderstood metric</article-title>
<source>Nature</source>
<year>2020</year>
<volume>583</volume>
<fpage>346</fpage>
<lpage>348</lpage>
<pub-id pub-id-type="doi">10.1038/d41586-020-02009-w</pub-id>
</element-citation>
</ref>
<ref id="R2">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blanco-Melo</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Nilsson-Payant</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Uhl</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hoagland</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Møller</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Jordan</surname>
<given-names>TX</given-names>
</name>
<name>
<surname>Oishi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Panis</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sachs</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>TT</given-names>
</name>
<etal/>
</person-group>
<article-title>Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19</article-title>
<source>Cell</source>
<year>2020</year>
<volume>181</volume>
<fpage>1036</fpage>
<lpage>1045</lpage>
<elocation-id>e9</elocation-id>
<pub-id pub-id-type="doi">10.1016/j.cell.2020.04.026</pub-id>
</element-citation>
</ref>
<ref id="R3">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carey</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Govande</surname>
<given-names>AA</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Hartley</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Kranzusch</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Elde</surname>
<given-names>NC</given-names>
</name>
</person-group>
<article-title>Recurrent Loss-of-Function Mutations Reveal Costs to OAS1 Antiviral Activity in Primates</article-title>
<source>Cell Host Microbe</source>
<year>2019</year>
<volume>25</volume>
<fpage>336</fpage>
<lpage>343</lpage>
<elocation-id>e4</elocation-id>
<pub-id pub-id-type="doi">10.1016/j.chom.2019.01.001</pub-id>
</element-citation>
</ref>
<ref id="R4">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cartegni</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>MQ</given-names>
</name>
<name>
<surname>Krainer</surname>
<given-names>AR</given-names>
</name>
</person-group>
<article-title>ESEfinder: A web resource to identify exonic splicing enhancers</article-title>
<source>Nucleic Acids Res</source>
<year>2003</year>
<volume>31</volume>
<fpage>3568</fpage>
<lpage>71</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkg616</pub-id>
</element-citation>
</ref>
<ref id="R5">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>UY</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>J-S</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y-J</given-names>
</name>
</person-group>
<article-title>Oligoadenylate synthase-like (OASL) proteins: dual functions and associations with diseases</article-title>
<source>Exp Mol Med</source>
<year>2015</year>
<volume>47</volume>
<elocation-id>e144</elocation-id>
<pub-id pub-id-type="doi">10.1038/emm.2014.110</pub-id>
</element-citation>
</ref>
<ref id="R6">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Di</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Elbahesh</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Brinton</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Characteristics of Human OAS1 Isoform Proteins</article-title>
<source>Viruses</source>
<year>2020</year>
<volume>12</volume>
<pub-id pub-id-type="doi">10.3390/v12020152</pub-id>
</element-citation>
</ref>
<ref id="R7">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ford</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Thanos</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>The transcriptional code of human IFN-beta gene expression</article-title>
<source>Biochim Biophys Acta</source>
<year>2010</year>
<volume>1799</volume>
<fpage>328</fpage>
<lpage>36</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbagrm.2010.01.010</pub-id>
</element-citation>
</ref>
<ref id="R8">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamano</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hijikata</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Itoyama</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Quy</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Phi</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>HT</given-names>
</name>
<name>
<surname>Ha</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Van Ban</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Matsushita</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Yanai</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kirikae</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>
<article-title>Polymorphisms of interferon-inducible genes OAS-1 and MxA associated with SARS in the Vietnamese population</article-title>
<source>Biochem Biophys Res Commun</source>
<year>2005</year>
<volume>329</volume>
<fpage>1234</fpage>
<lpage>9</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbrc.2005.02.101</pub-id>
</element-citation>
</ref>
<ref id="R9">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harko</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Lobo</surname>
<given-names>FSN</given-names>
</name>
<name>
<surname>Mak</surname>
<given-names>MK</given-names>
</name>
</person-group>
<article-title>Exact analytical solutions of the Susceptible-Infected-Recovered (SIR) epidemic model and of the SIR model with equal death and birth rates</article-title>
<source>Appl Math Comput</source>
<year>2014</year>
<volume>236</volume>
<fpage>184</fpage>
<lpage>194</lpage>
<pub-id pub-id-type="doi">10.1016/j.amc.2014.03.030</pub-id>
</element-citation>
</ref>
<ref id="R10">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>D</given-names>
</name>
<name>
<surname>de Vlas</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fontanet</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Plancoulaine</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zhan</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>
<article-title>Association of SARS susceptibility with single nucleic acid polymorphisms of OAS1 and MxA genes: a case-control study</article-title>
<source>BMC Infect Dis</source>
<year>2006</year>
<volume>6</volume>
<fpage>106</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2334-6-106</pub-id>
</element-citation>
</ref>
<ref id="R11">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hung</surname>
<given-names>IF-N</given-names>
</name>
<name>
<surname>Lung</surname>
<given-names>K-C</given-names>
</name>
<name>
<surname>Tso</surname>
<given-names>EY-K</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>TW-H</given-names>
</name>
<name>
<surname>Chu</surname>
<given-names>M-Y</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>Y-Y</given-names>
</name>
<name>
<surname>Lo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Tam</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Shum</surname>
<given-names>H-P</given-names>
</name>
<etal/>
</person-group>
<article-title>Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial</article-title>
<source>Lancet (London, England)</source>
<year>2020</year>
<volume>395</volume>
<fpage>1695</fpage>
<lpage>1704</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(20)31042-4</pub-id>
</element-citation>
</ref>
<ref id="R12">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ibsen</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Gad</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Andersen</surname>
<given-names>LL</given-names>
</name>
<name>
<surname>Hornung</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Julkunen</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Sarkar</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Hartmann</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Structural and functional analysis reveals that human OASL binds dsRNA to enhance RIG-I signaling</article-title>
<source>Nucleic Acids Res</source>
<year>2015</year>
<volume>43</volume>
<fpage>5236</fpage>
<lpage>48</lpage>
<pub-id pub-id-type="doi">10.1093/nar/gkv389</pub-id>
</element-citation>
</ref>
<ref id="R13">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kjær</surname>
<given-names>KH</given-names>
</name>
<name>
<surname>Pahus</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hansen</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Poulsen</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Christensen</surname>
<given-names>EI</given-names>
</name>
<name>
<surname>Justesen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Martensen</surname>
<given-names>PM</given-names>
</name>
</person-group>
<article-title>Mitochondrial localization of the OAS1 p46 isoform associated with a common single nucleotide polymorphism</article-title>
<source>BMC Cell Biol</source>
<year>2014</year>
<volume>15</volume>
<fpage>1</fpage>
<lpage>14</lpage>
<pub-id pub-id-type="doi">10.1186/1471-2121-15-33</pub-id>
</element-citation>
</ref>
<ref id="R14">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>R-J</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H-P</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>B-L</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>W-C</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>C-L</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y-L</given-names>
</name>
</person-group>
<article-title>Distinct antiviral roles for human 2’,5’-oligoadenylate synthetase family members against dengue virus infection</article-title>
<source>J Immunol</source>
<year>2009</year>
<volume>183</volume>
<fpage>8035</fpage>
<lpage>43</lpage>
<pub-id pub-id-type="doi">10.4049/jimmunol.0902728</pub-id>
</element-citation>
</ref>
<ref id="R15">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marcus</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Novembre</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Visualizing the geography of genetic variants</article-title>
<source>Bioinformatics</source>
<year>2017</year>
<volume>33</volume>
<fpage>594</fpage>
<lpage>595</lpage>
<pub-id pub-id-type="doi">10.1093/bioinformatics/btw643</pub-id>
</element-citation>
</ref>
<ref id="R16">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mendez</surname>
<given-names>FL</given-names>
</name>
<name>
<surname>Watkins</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Hammer</surname>
<given-names>MF</given-names>
</name>
</person-group>
<article-title>Neandertal origin of genetic variation at the cluster of OAS immunity genes</article-title>
<source>Mol Biol Evol</source>
<year>2013</year>
<volume>30</volume>
<fpage>798</fpage>
<lpage>801</lpage>
<pub-id pub-id-type="doi">10.1093/molbev/mst004</pub-id>
</element-citation>
</ref>
<ref id="R17">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monk</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Marsden</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Tear</surname>
<given-names>VJ</given-names>
</name>
<name>
<surname>Brookes</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Batten</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Mankowski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gabbay</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Holgate</surname>
<given-names>ST</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>L-P</given-names>
</name>
<name>
<surname>Clark</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>
<article-title>Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial</article-title>
<source>Lancet Respir Med</source>
<year>2021</year>
<volume>9</volume>
<fpage>196</fpage>
<lpage>206</lpage>
<pub-id pub-id-type="doi">10.1016/S2213-2600(20)30511-7</pub-id>
</element-citation>
</ref>
<ref id="R18">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nile</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Nile</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Kai</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons</article-title>
<source>Cytokine Growth Factor Rev</source>
<year>2020</year>
<volume>53</volume>
<fpage>66</fpage>
<lpage>70</lpage>
<pub-id pub-id-type="doi">10.1016/j.cytogfr.2020.05.002</pub-id>
</element-citation>
</ref>
<ref id="R19">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noguchi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hamano</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Matsushita</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Hijikata</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Nagase</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Keicho</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>Differential effects of a common splice site polymorphism on the generation of OAS1 variants in human bronchial epithelial cells</article-title>
<source>Hum Immunol</source>
<year>2013</year>
<volume>74</volume>
<fpage>395</fpage>
<lpage>401</lpage>
<pub-id pub-id-type="doi">10.1016/j.humimm.2012.11.011</pub-id>
</element-citation>
</ref>
<ref id="R20">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pairo-Castineira</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Clohisey</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Klaric</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bretherick</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Rawlik</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Pasko</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Parkinson</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Fourman</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Furniss</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Genetic mechanisms of critical illness in COVID-19</article-title>
<source>Nature</source>
<year>2021</year>
<volume>591</volume>
<fpage>92</fpage>
<lpage>98</lpage>
<pub-id pub-id-type="doi">10.1038/s41586-020-03065-y</pub-id>
</element-citation>
</ref>
<ref id="R21">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sadler</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>BRG</given-names>
</name>
</person-group>
<article-title>Interferon-inducible antiviral effectors</article-title>
<source>Nat Rev Immunol</source>
<year>2008</year>
<volume>8</volume>
<fpage>559</fpage>
<lpage>68</lpage>
<pub-id pub-id-type="doi">10.1038/nri2314</pub-id>
</element-citation>
</ref>
<ref id="R22">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sakuma</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Iida</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hagiwara</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Deciphering targeting rules of splicing modulator compounds: case of TG003</article-title>
<source>BMC Mol Biol</source>
<year>2015</year>
<volume>16</volume>
<fpage>16</fpage>
<pub-id pub-id-type="doi">10.1186/s12867-015-0044-6</pub-id>
</element-citation>
</ref>
<ref id="R23">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schlee</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hartmann</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Discriminating self from non-self in nucleic acid sensing</article-title>
<source>Nat Rev Immunol</source>
<year>2016</year>
<volume>16</volume>
<fpage>566</fpage>
<lpage>80</lpage>
<pub-id pub-id-type="doi">10.1038/nri.2016.78</pub-id>
</element-citation>
</ref>
<ref id="R24">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwanke</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Stempel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Brinkmann</surname>
<given-names>MM</given-names>
</name>
</person-group>
<article-title>Of Keeping and Tipping the Balance: Host Regulation and Viral Modulation of IRF3-Dependent IFNB1 Expression</article-title>
<source>Viruses</source>
<year>2020</year>
<volume>12</volume>
<pub-id pub-id-type="doi">10.3390/v12070733</pub-id>
</element-citation>
</ref>
<ref id="R25">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shalhoub</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Interferon beta-1b for COVID-19</article-title>
<source>Lancet (London, England)</source>
<year>2020</year>
<volume>395</volume>
<fpage>1670</fpage>
<lpage>1671</lpage>
<pub-id pub-id-type="doi">10.1016/S0140-6736(20)31101-6</pub-id>
</element-citation>
</ref>
<ref id="R26">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shibata</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ajiro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hagiwara</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Mechanism-Based Personalized Medicine for Cystic Fibrosis by Suppressing Pseudo Exon Inclusion</article-title>
<source>Cell Chem Biol</source>
<year>2020</year>
<volume>27</volume>
<fpage>1472</fpage>
<lpage>1482</lpage>
<elocation-id>e6</elocation-id>
<pub-id pub-id-type="doi">10.1016/j.chembiol.2020.08.013</pub-id>
</element-citation>
</ref>
<ref id="R27">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soetaert</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Petzoldt</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Setzer</surname>
<given-names>RW</given-names>
</name>
</person-group>
<article-title>Solving Differential Equations in R : Package deSolve</article-title>
<source>J Stat Softw</source>
<year>2010</year>
<volume>33</volume>
<pub-id pub-id-type="doi">10.18637/jss.v033.i09</pub-id>
</element-citation>
</ref>
<ref id="R28">
<element-citation publication-type="journal">
<collab>The COVID-19 Host Genetics Initiative</collab>
<article-title>Mapping the human genetic architecture of COVID-19 by worldwide meta-analysis</article-title>
<source>medRxiv</source>
<year>2021</year>
<elocation-id>2021.03.10.21252820</elocation-id>
<pub-id pub-id-type="doi">10.1101/2021.03.10.21252820</pub-id>
</element-citation>
</ref>
<ref id="R29">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeberg</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Pääbo</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>A genomic region associated with protection against severe COVID-19 is inherited from Neandertals</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2021</year>
<volume>118</volume>
<pub-id pub-id-type="doi">10.1073/pnas.2026309118</pub-id>
</element-citation>
</ref>
<ref id="R30">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Butler-Laporte</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Nakanishi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Morrison</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Afilalo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Afilalo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Laurent</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Pietzner</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kerrison</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Brunet-Ratnasingham</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>
<article-title>A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity</article-title>
<source>Nat Med</source>
<year>2021</year>
<pub-id pub-id-type="doi">10.1038/s41591-021-01281-1</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<title>
<italic>OAS1-3</italic> loci have COVID-19 associated SNPs and respond to SARS-CoV-2</title>
<p>Positions and GWAS p-values for SNPs on <italic>OAS1, OAS3</italic>, and <italic>OAS2</italic> gene loci. GWAS results for confirmed COVID-19 cases with very severe respiratory conditions (a), hospitalized COVID-19 patients (b), and all COVID-19 patients (c), reported by COVID-19 Host Genome Initiative groups, are shown (Reported by COVID-19 Host Genome Initiative groups). Red and blue horizontal lines show the p-value positions of 5E-8 and 1E-5, respectively. The position of rs10774671 SNP is shown with a green dotted line and red arrows.</p>
</caption>
<graphic xlink:href="EMS134154-f001"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<title>CLK inhibitor CaNDY induces splice-switching in <italic>OAS1</italic> rs10774671 A allele.</title>
<p>
<bold>a</bold>, Allele-dependent <italic>OAS1</italic> alternative splicing. Pre-mRNA of <italic>OAS1</italic>, with the rs10774671 G-allele at - 1 position of exon 6 splice acceptor (SA), dominantly produces the <italic>p46</italic> variant, whereas the A-allele leads to alternative splicing to produce the <italic>p42</italic>, <italic>p48</italic>, <italic>p44a</italic>, and <italic>p44b</italic> variants with differences in the last exon (yellow boxes). <bold>b</bold>, The SRSF6 binding motif (red letters) present in close vicinity of the U1 binding site of <italic>OAS1</italic> donor site for <italic>p44a</italic>/<italic>p44b</italic>/<italic>p48</italic> splicing. Blue dots indicate U1snRNA pairing. <bold>c</bold>, Western blot of U1-70k and phosphorylated SRSF6 (p-SRSF6) for RNA pull-down products of <italic>OAS1</italic> exon 5 splice donor (SD) sequence in Calu-3 cells treated with 0.1% DMSO or 10 μM CaNDY. Input, input samples; bait (-), negative control products without the bait RNA oligo. ACTB served as the loading control. <bold>d</bold>, RT-PCR for <italic>OAS1</italic> alternative splicing profile in Daudi (G/G allele) and Calu-3 (A/A allele) cells treated with 0.1% DMSO or 10 μM CaNDY for 24 h. <italic>ACTB</italic> served as a loading control. <bold>e</bold>, RNA-Seq results indicated by a Sashimi plot for a region covering <italic>p42</italic>, <italic>p44a</italic>, and <italic>p46</italic>. <bold>f</bold>, Numbers of splice-junction reads for each <italic>OAS1</italic> splice variants. Dots, read number of repeats; error bars, ±SD. n.s., p ≥ 0.05; *, p &lt; 0.05; **, p&lt; 0.01 by Student’s t-test.</p>
<p>Figure 2<bold>-source data 1 (Separated File)</bold>
</p>
<p>Original Western blot files for Figure 2C.</p>
<p>Figure 2<bold>-source data 2 (Separated File)</bold>
</p>
<p>Original gel electrophoresis files for Figure 2D.</p>
</caption>
<graphic xlink:href="EMS134154-f002"/>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<title>Pre-treatment with CaNDY confers Calu-3 cells with resistance against SARS-CoV-2 infection via activation of the RNase L and interferon pathways.</title>
<p>a, A scheme for the pre-treatment of CaNDY, virus titer assay. b, Box plots showing logarithm translated virus titers. The shown values are corrected for batch effects (See methods and <xref ref-type="supplementary-material" rid="SD1">Table S4</xref>). c, Bar-plot for cleaved RNA products and 28S rRNA measured with the BioAnalyzer system for the RNA samples from Calu-3 cells, before and after the viral infection for 24 h, with and without CaNDY treatments. Error bars, ±SD; *, p &lt; 0.05; by Student’s t-test. d, RT-PCR results for <italic>IFNB1</italic> mRNA. e, Bar-plot for quantified IFNB1/ACTB in the infected cells based on RT-PCR results. Error bars, ±SD; **, p &lt; 0.01; by Student’s t-test. f, A summary of the current study.</p>
<p>Figure 3<bold>-source data 1 (Separated File)</bold>
</p>
<p>Original BioAnalyzer system result file for Figure 3C.</p>
<p>Figure 3<bold>-source data 2 (Separated File)</bold>
</p>
<p>Original gel electrophoresis files for Figure 3D.</p>
</caption>
<graphic xlink:href="EMS134154-f003"/>
</fig>
<table-wrap id="T1" position="float" orientation="portrait">
<label>Table 1</label>
<caption>
<title>SNPs on <italic>OAS1</italic> locus associated with very severe respiratory confirmed COVID-19 (p &lt; 5 × 10<sup>−8</sup>).</title>
</caption>
<table frame="box" rules="all">
<thead>
<tr>
<th align="left" valign="top">Chr</th>
<th align="left" valign="top">Pos</th>
<th align="left" valign="top">ID</th>
<th align="left" valign="top">p-value<xref ref-type="table-fn" rid="TFN1">*</xref>
</th>
<th align="left" valign="top">log (Odds Ratio)<xref ref-type="table-fn" rid="TFN1">*</xref>
</th>
<th align="left" valign="top">Ref</th>
<th align="left" valign="top">Alt</th>
<th align="left" valign="top">Location to OAS1 transcript variant 1 (p46)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="top">12</td>
<td align="left" valign="top">112,912,991</td>
<td align="left" valign="top">rs2057778</td>
<td align="left" valign="top">6.86 × 10<sup>−10</sup>
</td>
<td align="left" valign="top">0.17</td>
<td align="left" valign="top">G</td>
<td align="left" valign="top">T</td>
<td align="left" valign="top">Intron 3 (1756th base of 5273nt.)</td>
</tr>
<tr>
<td align="left" valign="top">12</td>
<td align="left" valign="top">112,914,354</td>
<td align="left" valign="top">rs4767023</td>
<td align="left" valign="top">1.70 × 10<sup>−10</sup>
</td>
<td align="left" valign="top">0.17</td>
<td align="left" valign="top">T</td>
<td align="left" valign="top">C</td>
<td align="left" valign="top">Intron 3 (3119th base of 5273nt.)</td>
</tr>
<tr>
<td align="left" valign="top">12</td>
<td align="left" valign="top">112,919,388</td>
<td align="left" valign="top">rs10774671</td>
<td align="left" valign="top">1.10 × 10<sup>−12</sup>
</td>
<td align="left" valign="top">0.18</td>
<td align="left" valign="top">G</td>
<td align="left" valign="top">A</td>
<td align="left" valign="top">Intron 5 (1688th base of 1688nt.)</td>
</tr>
<tr>
<td align="left" valign="top">12</td>
<td align="left" valign="top">112,919,404</td>
<td align="left" valign="top">rs1131476</td>
<td align="left" valign="top">4.54 × 10<sup>−12</sup>
</td>
<td align="left" valign="top">0.18</td>
<td align="left" valign="top">G</td>
<td align="left" valign="top">A</td>
<td align="left" valign="top">Exon 6 (16th base of 515nt., CDS, Ala&gt;Thr)</td>
</tr>
<tr>
<td align="left" valign="top">12</td>
<td align="left" valign="top">112,919,637</td>
<td align="left" valign="top">rs2660</td>
<td align="left" valign="top">2.68 × 10<sup>−12</sup>
</td>
<td align="left" valign="top">0.19</td>
<td align="left" valign="top">G</td>
<td align="left" valign="top">A</td>
<td align="left" valign="top">Exon 6 (249th base of 515nt., 3' UTR)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TFN1">
<label>*</label>
<p id="P31">From GWAS anslysis for very severe respiratory confirmed COVID-19</p>
</fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
